Cheng-Hsin General Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2011
NCT01710007
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cheng-Hsin General Hospital | Cheng Hsin Hospital

Active Ingredients

Drugs in Phase 4 Trials (4)

dapagliflozin (farxiga) (1 trial)

Ocedurenone (1 trial)

sacubitril (Entresto) (1 trial)

valsartan (diovan) (1 trial)

Drugs in Phase 3 Trials (2)

atorvastatin (lipitor) (1 trial)

pitavastatin (livalo) (1 trial)

Drugs in Phase 2 Trials (1)

onabotulinumtoxinA (Botox) (1 trial)

Drugs in Other Trials (1)

vigiis 101-lab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 4)

Hypercholesterolemia (Phase 3)

Hypotension (Phase 4)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 8